[{"id":"a3ff3bf1-6fbc-4e00-b8e0-454d7fb78cce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687136","created_at":"2023-01-18T15:59:53.342Z","updated_at":"2025-02-25T13:41:23.007Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors","source_id_and_acronym":"NCT05687136","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"08f4f7cb-1de9-4017-ba99-77f7d20628d0","acronym":"ARTS-021-1001","url":"https://clinicaltrials.gov/study/NCT05867251","created_at":"2023-05-19T13:05:01.323Z","updated_at":"2025-02-25T16:46:48.865Z","phase":"Phase 1/2","brief_title":"Study of AVZO-021 in Patients with Advanced Solid Tumors","source_id_and_acronym":"NCT05867251 - ARTS-021-1001","lead_sponsor":"Avenzo Therapeutics, Inc.","biomarkers":" HER-2 • CCNE1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • carboplatin • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • Trodelvy (sacituzumab govitecan-hziy) • AVZO-021"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 08/30/2023","start_date":" 08/30/2023","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2025-02-05"},{"id":"f4599b74-514d-415f-a4c1-0ad32a88ef07","acronym":"A071401","url":"https://clinicaltrials.gov/study/NCT02523014","created_at":"2021-01-18T12:11:52.655Z","updated_at":"2025-02-25T13:11:46.229Z","phase":"Phase 2","brief_title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas","source_id_and_acronym":"NCT02523014 - A071401","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation","tags":["PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-15"},{"id":"676dfb5a-6692-4639-bd2b-6232077e3caa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02896335","created_at":"2021-01-18T14:12:49.075Z","updated_at":"2025-02-25T16:05:12.381Z","phase":"Phase 2","brief_title":"Palbociclib and Pembrolizumab in Central Nervous System Metastases","source_id_and_acronym":"NCT02896335","lead_sponsor":"Massachusetts General Hospital","biomarkers":" CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" CCNE1 amplification • CCND1 amplification • CDK4 amplification","tags":["CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCNE1 amplification • CCND1 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-11-21"},{"id":"1251a894-93e6-4c49-a11d-e5400df1cba5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05605509","created_at":"2022-11-04T16:58:13.524Z","updated_at":"2024-07-02T16:34:26.676Z","phase":"Phase 2","brief_title":"RP-6306 in Patients With Advanced Cancer","source_id_and_acronym":"NCT05605509","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • KRAS • TP53 • CCNE1 • UGT1A1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1","tags":["HER-2 • KRAS • TP53 • CCNE1 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (RP-6306)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 05/24/2023","start_date":" 05/24/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-12"},{"id":"7f306611-7670-46f5-9d82-2776f52be9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633239","created_at":"2022-11-25T17:57:43.239Z","updated_at":"2024-07-02T16:34:37.807Z","phase":"Phase 1","brief_title":"Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT04633239","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • HRD • CCNE1 • BRCA • CASP3","pipe":" | ","alterations":" HRD","tags":["BRCA1 • HRD • CCNE1 • BRCA • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-06"},{"id":"cf414f6a-54f9-4ccf-b2fd-2b1f78958212","acronym":"INX-315-01","url":"https://clinicaltrials.gov/study/NCT05735080","created_at":"2023-02-21T16:01:43.523Z","updated_at":"2024-07-02T16:35:02.015Z","phase":"Phase 1/2","brief_title":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","source_id_and_acronym":"NCT05735080 - INX-315-01","lead_sponsor":"Incyclix Bio","biomarkers":" HER-2 • ER • CCNE1","pipe":" | ","alterations":" HER-2 negative • CCNE1 amplification","tags":["HER-2 • ER • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CCNE1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INX-315"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-22"},{"id":"d7d6598c-31e5-4bc3-b406-5e9ff144fe1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03834740","created_at":"2021-01-18T18:56:01.539Z","updated_at":"2024-07-02T16:35:04.374Z","phase":"Phase 1","brief_title":"A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection","source_id_and_acronym":"NCT03834740","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression","tags":["PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 02/18/2022","study_completion_date":" 02/18/2022","last_update_posted":"2024-05-10"},{"id":"f851164b-12cc-4802-a431-f0b4ed742c5e","acronym":"VELA","url":"https://clinicaltrials.gov/study/NCT05252416","created_at":"2022-02-23T19:55:05.515Z","updated_at":"2024-07-02T16:35:07.979Z","phase":"Phase 1/2","brief_title":"(VELA) Study of BLU-222 in Advanced Solid Tumors","source_id_and_acronym":"NCT05252416 - VELA","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" HER-2 • CCNE1","pipe":" | ","alterations":" HER-2 negative • CCNE1 amplification","tags":["HER-2 • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CCNE1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Kisqali (ribociclib) • fulvestrant • cirtociclib (BLU-222)"],"overall_status":"Recruiting","enrollment":" Enrollment 366","initiation":"Initiation: 04/07/2022","start_date":" 04/07/2022","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-04-23"},{"id":"c92b8794-1c47-49f1-88e3-148924bb13cc","acronym":"BISCAY","url":"https://clinicaltrials.gov/study/NCT02546661","created_at":"2021-01-18T12:19:22.211Z","updated_at":"2024-07-02T16:35:15.193Z","phase":"Phase 1","brief_title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02546661 - BISCAY","lead_sponsor":"AstraZeneca","biomarkers":" HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL","pipe":" | ","alterations":" PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification","tags":["HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-12"},{"id":"266a2712-9c1f-4bc2-b88c-002f9d951d7d","acronym":"GOG-3039","url":"https://clinicaltrials.gov/study/NCT04393285","created_at":"2023-12-13T16:16:37.842Z","updated_at":"2024-07-02T16:35:26.346Z","phase":"Phase 2","brief_title":"Abemaciclib and Letrozole to Treat Endometrial Cancer","source_id_and_acronym":"NCT04393285 - GOG-3039","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20","pipe":" | ","alterations":" CCND1 expression • CCND1 mutation","tags":["ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/10/2020","start_date":" 10/10/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-13"},{"id":"37f91647-0805-4a4c-8991-be19e1ffd9fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03253679","created_at":"2021-01-18T16:04:25.042Z","updated_at":"2024-07-02T16:35:33.239Z","phase":"Phase 2","brief_title":"AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification","source_id_and_acronym":"NCT03253679","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CCNE1","pipe":" | ","alterations":" CCNE1 amplification","tags":["CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCNE1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/16/2019","start_date":" 01/16/2019","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2022","study_completion_date":" 10/31/2022","last_update_posted":"2023-10-17"},{"id":"12b373a9-f27e-4aa8-b2c5-2cb259826f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03718091","created_at":"2021-01-18T18:13:18.198Z","updated_at":"2024-07-02T16:35:43.598Z","phase":"Phase 2","brief_title":"M6620 (VX-970) in Selected Solid Tumors","source_id_and_acronym":"NCT03718091","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2023-07-07"},{"id":"ef34af80-bc5d-43b8-a58e-cbcbf1d862b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02797977","created_at":"2021-01-18T13:43:39.707Z","updated_at":"2024-07-02T16:35:45.278Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects","source_id_and_acronym":"NCT02797977","lead_sponsor":"Sierra Oncology LLC - a GSK company","biomarkers":" TP53 • BRCA1 • BRCA2 • MSI • RB1 • CCNE1 • BRCA","pipe":" | ","alterations":" MSI-H/dMMR • BRCA wild-type","tags":["TP53 • BRCA1 • BRCA2 • MSI • RB1 • CCNE1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • SRA737"],"overall_status":"Completed","enrollment":" Enrollment 153","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 04/08/2020","primary_completion_date":" 04/08/2020","study_txt":" Completion: 04/08/2020","study_completion_date":" 04/08/2020","last_update_posted":"2023-06-22"},{"id":"f02dddc5-2a04-40ac-a7c0-6ae1b37c773a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02797964","created_at":"2021-01-18T13:43:37.507Z","updated_at":"2024-07-02T16:35:45.492Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer","source_id_and_acronym":"NCT02797964","lead_sponsor":"Sierra Oncology LLC - a GSK company","biomarkers":" TP53 • BRCA1 • BRCA2 • MSI • CCNE1 • RAD50","pipe":" | ","alterations":" MSI-H/dMMR","tags":["TP53 • BRCA1 • BRCA2 • MSI • CCNE1 • RAD50"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SRA737"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 10/28/2019","primary_completion_date":" 10/28/2019","study_txt":" Completion: 10/28/2019","study_completion_date":" 10/28/2019","last_update_posted":"2023-06-16"},{"id":"177f8b5d-8348-4b32-a118-0b00e538da2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05431582","created_at":"2022-06-24T15:56:46.001Z","updated_at":"2024-07-02T16:35:45.607Z","phase":"Phase 1","brief_title":"Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors","source_id_and_acronym":"NCT05431582","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CCNE1","pipe":" | ","alterations":" TP53 mutation • CCNE1 amplification • TP53 amplification","tags":["TP53 • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CCNE1 amplification • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • azenosertib (ZN-c3)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/14/2022","start_date":" 12/14/2022","primary_txt":" Primary completion: 12/14/2022","primary_completion_date":" 12/14/2022","study_txt":" Completion: 12/14/2022","study_completion_date":" 12/14/2022","last_update_posted":"2023-06-15"},{"id":"b2d3e38f-bf00-4920-aff3-f61daeca6754","acronym":"","url":"https://clinicaltrials.gov/study/NCT02873975","created_at":"2021-01-18T14:06:40.199Z","updated_at":"2024-07-02T16:36:02.020Z","phase":"Phase 2","brief_title":"A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency","source_id_and_acronym":"NCT02873975","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • MYC amplification • PALB2 mutation • CCNE1 amplification • FBXW7 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • MYC amplification • PALB2 mutation • CCNE1 amplification • FBXW7 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 10/12/2016","start_date":" 10/12/2016","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2022-10-21"},{"id":"ee2f1151-0f4f-4a69-942e-a345a7a08618","acronym":"","url":"https://clinicaltrials.gov/study/NCT05497076","created_at":"2022-11-08T19:26:21.936Z","updated_at":"2024-07-02T16:36:05.643Z","phase":"","brief_title":"the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy","source_id_and_acronym":"NCT05497076","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" CDKN2A • RB1 • CCND1 • CCNE1 • CDK4 • CDKN2B • CCND2 • CCND3","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation","tags":["CDKN2A • RB1 • CCND1 • CCNE1 • CDK4 • CDKN2B • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKang (dalpiciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-08-11"},{"id":"6b824df4-f7d8-4c9b-bf72-19e63cd135b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03509246","created_at":"2021-01-18T17:16:27.500Z","updated_at":"2024-07-02T16:36:51.322Z","phase":"Phase 2","brief_title":"Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients","source_id_and_acronym":"NCT03509246","lead_sponsor":"Seoul National University Hospital","biomarkers":" CCNE1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["CCNE1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • pegylated liposomal doxorubicin • doxorubicin liposomal"],"overall_status":"Unknown status","enrollment":" Enrollment 44","initiation":"Initiation: 05/15/2018","start_date":" 05/15/2018","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2020-01-14"},{"id":"274b6789-cafa-442a-b349-5cb43132ed40","acronym":"","url":"https://clinicaltrials.gov/study/NCT02656849","created_at":"2021-01-18T12:56:12.287Z","updated_at":"2025-02-25T17:23:00.771Z","phase":"Phase 2","brief_title":"BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors","source_id_and_acronym":"NCT02656849","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • CCNE1 • MCL1","pipe":" | ","alterations":" MYC amplification • CCNE1 amplification • MCL1 amplification","tags":["MYC • CCNE1 • MCL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC amplification • CCNE1 amplification • MCL1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e roniciclib (BAY1000394)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2016-07-01"}]